UCB's Phase IIb padsevonil ARISE study fails endpoints

13 March 2020
ucb_hq_brussels_large

Belgium’s largest drugmaker UCB (Euronext Brussels: UCB) today announced disappointing top-line results from ARISE (NCT03373383), the first of two adequate and well-controlled studies, investigating the efficacy and safety of padsevonil for the treatment of observable focal-onset seizures in adults with drug-resistant epilepsy.

The company’s shares fell 3.04% to 73.30 euros, while the Euronext Brussels index rallied more than 4% by mid-morning.

This randomized, double-blind, placebo-controlled Phase IIb study did not reach statistical significance for either of the primary endpoints, change from baseline in observable focal-onset seizure frequency and 75% responder rate for padsevonil compared with placebo over the 12-week maintenance period. Padsevonil was generally well-tolerated and its safety profile was consistent with that seen in earlier studies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical